We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Curcumin Bioavailability in Glioblastoma Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01712542
First Posted: October 23, 2012
Last Update Posted: June 4, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Stephan Dützmann, Johann Wolfgang Goethe University Hospitals
  Purpose
Measuring the bioavailability of orally administered curcumin in the tumors of glioblastoma patients.

Condition Phase
Patient Harboring Glioblastoma That Will Undergo Surgery Early Phase 1

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Measurement of Intratumoral Concentration of the Nontoxic Natural Compound Curcumin in Glioblastoma Patients

Resource links provided by NLM:


Further study details as provided by Stephan Dützmann, Johann Wolfgang Goethe University Hospitals:

Primary Outcome Measures:
  • Concentration of Curcumin in Glioblastoma [ Time Frame: At Tumor resection ]
    At the time of surgery


Biospecimen Retention:   Samples Without DNA
Tumor tissue

Estimated Enrollment: 15
Study Start Date: October 2012
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients harboring Glioblastoma
Criteria

Inclusion Criteria:

  • Patients harboring Glioblastoma
  • Patient will undergo surgery

Exclusion Criteria:

  • BMI > 30
  • Liver and Kidney Function so compromised that medication is prescribed
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01712542


Locations
Germany
Department of Neurosurgery, Johann Wolfgang Goethe-University
Frankfurt, Hessen, Germany, 60528
Sponsors and Collaborators
Johann Wolfgang Goethe University Hospital
Investigators
Principal Investigator: Stephan Duetzmann Goethe University
  More Information

Additional Information:
Publications:
Responsible Party: Stephan Dützmann, M.D., Johann Wolfgang Goethe University Hospitals
ClinicalTrials.gov Identifier: NCT01712542     History of Changes
Other Study ID Numbers: JohannWGUH_Curcumin-01
First Submitted: October 20, 2012
First Posted: October 23, 2012
Last Update Posted: June 4, 2013
Last Verified: June 2013

Additional relevant MeSH terms:
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Curcumin
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action